We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-2.04%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$714M
AUM Growth
+$37.8M
Cap. Flow
+$141M
Cap. Flow %
19.78%
Top 10 Hldgs %
80.08%
Holding
30
New
8
Increased
5
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$55.1M
2
AAPL icon
Apple
AAPL
+$52.2M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$50M
4
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$6.17M
5
FOLD
Amicus Therapeutics
FOLD
+$5.71M

Top Sells

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$21.9M
2
KIDS icon
OrthoPediatrics
KIDS
+$19.9M
3
XLRN
Acceleron Pharma
XLRN
+$3.25M
4
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$3.08M
5
DERM
Dermira, Inc.
DERM
+$2.72M

Sector Composition

Rank Sector Weight
1 Healthcare 79.61%
2 Technology 7.43%
3 Communication Services 7.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENT
26
DELISTED
Intersect ENT, Inc
XENT
$3.12M 0.44%
+136,885
New +$3.69M
COGT icon
27
Cogent Biosciences
COGT
$7.24B
$1.24M 0.17%
118,360
– –
PTGX icon
28
Protagonist Therapeutics
PTGX
$8.8B
$289K 0.04%
+23,901
New +$264K
DERM
29
DELISTED
Dermira, Inc.
DERM
– –
-201,059
Closed -$2.72M
1
2

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return

Novo Holdings A/S's Q2 2019 Portfolio in Review

As of Q2 2019, Novo Holdings A/S held 30 positions worth $714M, up 5.6% from $676M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Novo Holdings A/S deployed $141M of net new capital in Q2 2019, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Milestone Pharmaceuticals: 2,674,470 shares worth $72.6M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 87% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Glaukos, an estimated $21.9M trimmed.

  • Novo Holdings A/S's largest Q2 2019 buy was Milestone Pharmaceuticals: 2,674,470 shares worth $72.6M.
  • Novo Holdings A/S added most to Amicus Therapeutics in Q2 2019, an estimated $5.71M increase.
  • Novo Holdings A/S's biggest Q2 2019 reduction was Glaukos, cutting an estimated $21.9M.
  • Novo Holdings A/S fully exited Dermira, Inc. in Q2 2019, selling an estimated $2.72M.
  • Novo Holdings A/S's ten largest holdings make up 80% of its $714M portfolio in Q2 2019.
  • Novo Holdings A/S opened 8 new positions and closed 1 in Q2 2019.
  • Novo Holdings A/S's portfolio value rose 5.6% quarter-over-quarter to $714M.

Based on Novo Holdings A/S's 13F filing for Q2 2019, filed 14 Aug 2019.